Buy Elevance Health

Logo for stock ELV (Elevance Health)

Amount

£
GBP

Latest price

$336.45
(£1.00 = $1.34)

Number of shares (est.)

0

Start investing today

Open an investment account in Emma and enjoy commission free stock trading. Capital at risk, other charges apply.

QR code linking to downloads for the Emma app.
Download on the App Store buttonGet it on Google Play button

Metrics

Market Cap

$76.834B

P/E ratio

13.24

EPS

$25.694

Beta

0.61

Dividend rate

$6.60

Dividend yield

1.94%

About

Elevance Health is a leading health benefits company dedicated to improving lives and communities, and making healthcare simpler. Through its affiliated companies, Elevance Health serves more than 110 million people, including approximately 43 million within its family of health plans. We aim to be the most innovative, valuable and inclusive partner.

CEO

Ms. Gail K. Boudreaux

Employees

103,158

Sector

Finance

Company HQ

INDIANAPOLIS, United States of America

News

Logo for news article #0 (ELEVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Elevance Health, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm)

ELEVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Elevance Health, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Elevance (ELV) To Contact Him Directly To Discuss Their Options

GlobeNewsWire

July 16, 2025

Logo for news article #1 (Elevance Health: Should You Buy ELV Stock Ahead Of Its Upcoming Earnings?)

Elevance Health: Should You Buy ELV Stock Ahead Of Its Upcoming Earnings?

Elevance Health (NYSE:ELV) is set to report its earnings on Thursday, July 17, 2025. For traders focused on events, analyzing past stock performance surrounding earnings announcements can yield valuable insights and potentially improve trading strategies.

Forbes

July 15, 2025

Logo for news article #2 (Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?)

Elevance to Report Q2 Earnings: Will Rising Costs Pressure Profits?

ELV's second-quarter earnings may face pressure as rising costs and lower Medicaid memberships offset strong revenue gains.

Zacks Investment Research

July 14, 2025

Emma logo
Facebook logoTiktok logoTwitter / X logoInstagram logo

© 2025 Emma Technologies Ltd. All Rights Reserved.

Emma is registered and incorporated in England and Wales.

Emma Technologies Ltd is an appointed representative of RiskSave Technologies Ltd, which is authorised and regulated by the Financial Conduct Authority (FRN 775330).

Payment services (Non MIFID or Deposit related products) for Emma Technologies Ltd are provided by The Currency Cloud Limited. Registered in England No. 06323311. Registered Office: Stewardship Building 1st Floor, 12 Steward Street London E1 6FQ. The Currency Cloud Limited is authorised by the Financial Conduct Authority under the Electronic Money Regulations 2011 for the issuing of electronic money (FRN: 900199). For more detail on how your money is protected please see here. You can also find Currency Cloud's Terms of Use here.

Emma Technologies is an Introducer Appointed Representative of Quint Group Limited and not a lender. Quint Group Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 669450). Monevo Limited is an Appointed Representative of TransUnion International UK Limited. TransUnion is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 737740). Emma Technologies introduces customers first to Quint Group Limited, as a licensed credit broker, who then refers on to Monevo Limited.

Emma is registered with the Financial Conduct Authority under the Payment Services Regulations 2017 for the provision of payment services.

Financial Conduct Authority Reg Nr: 794952.
Company Registration Number: 10578464.
Data Protection Registration Number: ZA241546.

All testimonials, reviews, opinions or case studies presented on our website may not be indicative of all customers. Results may vary and customers agree to proceed at their own risk.